Author:
Krzyzewska I. M.,Maas S. M.,Henneman P.,Lip K. v. d.,Venema A.,Baranano K.,Chassevent A.,Aref-Eshghi E.,van Essen A. J.,Fukuda T.,Ikeda H.,Jacquemont M.,Kim H.-G.,Labalme A.,Lewis S. M. E.,Lesca G.,Madrigal I.,Mahida S.,Matsumoto N.,Rabionet R.,Rajcan-Separovic E.,Qiao Y.,Sadikovic B.,Saitsu H.,Sweetser D. A.,Alders M.,Mannens M. M. A. M.
Abstract
Abstract
SETD1B is a component of a histone methyltransferase complex that specifically methylates Lys-4 of histone H3 (H3K4) and is responsible for the epigenetic control of chromatin structure and gene expression. De novo microdeletions encompassing this gene as well as de novo missense mutations were previously linked to syndromic intellectual disability (ID). Here, we identify a specific hypermethylation signature associated with loss of function mutations in the SETD1B gene which may be used as an epigenetic marker supporting the diagnosis of syndromic SETD1B-related diseases. We demonstrate the clinical utility of this unique epi-signature by reclassifying previously identified SETD1B VUS (variant of uncertain significance) in two patients.
Publisher
Springer Science and Business Media LLC
Subject
Genetics(clinical),Developmental Biology,Genetics,Molecular Biology
Cited by
51 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献